Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
News about Atara Biotherapeutics, Inc. (NASDAQ: ATRA) centers on its development of allogeneic T-cell immunotherapies and the regulatory and business milestones associated with its Epstein-Barr virus (EBV)-specific platform. Atara describes itself as a leader in T-cell immunotherapy, focused on off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, with headquarters in Southern California. Much of the company’s recent news flow has highlighted progress and challenges around tabelecleucel (tab-cel or EBVALLO), its EBV-specific T-cell therapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Investors following ATRA news can expect updates on FDA interactions, including Biologics License Application (BLA) submissions, Priority Review status, Prescription Drug User Fee Act (PDUFA) target action dates, and Complete Response Letters. Releases have detailed how Atara and its partner Pierre Fabre Laboratories addressed Good Manufacturing Practice (GMP) observations, transferred the tabelecleucel IND and BLA, and responded to evolving FDA positions on the adequacy of the pivotal ALLELE study for accelerated approval.
Company news also covers financial results and corporate restructuring, such as quarterly earnings releases, changes in research and development and general and administrative expenses, workforce reductions, lease amendments, and the impact of tabelecleucel-related milestone payments and commercialization revenue. In addition, Atara has issued updates on its strategic alternatives review, describing potential transactions it may consider to maximize shareholder value.
For readers tracking ATRA, this news stream provides insight into Atara’s clinical and regulatory trajectory, its partnership with Pierre Fabre Laboratories on tabelecleucel/EBVALLO, and the company’s evolving cost structure and strategic direction. Regularly reviewing these updates can help contextualize movements in ATRA stock and developments in the EBV-focused cell therapy space.
Atara Biotherapeutics (NASDAQ: ATRA) will have its CEO, Pascal Touchon, participate in a cell therapy panel at the Cowen 42nd Annual Virtual Healthcare Conference on March 9, 2022, at 9:10 a.m. EST. The event emphasizes Atara's leadership in T-cell immunotherapy, particularly leveraging its allogeneic Epstein-Barr virus (EBV) platform for cancer and autoimmune disease treatments. A live webcast will be available on their website, with an archived replay accessible for 30 days post-presentation.
Atara Biotherapeutics (Nasdaq: ATRA) announced that a U.S. BLA submission for tab-cel is not expected in Q2 2022 due to further FDA alignment needed. However, the EU approval is on track for Q4 2022. The company reported a Q4 2021 net loss of $93.3 million and a total operating expense increase of 18% compared to the previous year. Significant advances were made in the development of ATA188 for progressive multiple sclerosis, which has received Fast Track designation from the FDA. Atara also entered a $100 million strategic manufacturing partnership with Fujifilm.
Atara Biotherapeutics (NASDAQ: ATRA) reported a serious adverse event (SAE) related to its autologous mesothelin CAR T therapy, ATA2271, during a Phase 1 study at Memorial Sloan Kettering Cancer Center (MSK). Following this event, MSK temporarily paused patient enrollment in the trial. The SAE involved a patient with prior malignancies and is currently under evaluation. Despite this setback, ongoing IND-enabling work for another CAR-T therapy, ATA3271, is unaffected. Atara emphasizes patient safety and intends to update stakeholders soon.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its fourth quarter and full year 2021 financial results on February 28, 2022. The announcement will be followed by a live conference call at 4:30 p.m. EST to discuss these results and provide a corporate update. Atara aims to deliver T-cell immunotherapy treatments for serious diseases using its unique Epstein-Barr virus T-cell platform, currently advancing several therapies, including tab-cel® for EBV-driven conditions, and ATA188 targeting multiple sclerosis.
Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 31,730 restricted stock units and stock options for 30,819 shares to new employees under its 2018 Inducement Plan, as per Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with 25% vesting after the first anniversary, while stock options also vest over four years with an exercise price of $15.47. This strategy aims to attract talent in T-cell immunotherapy to further develop treatments for cancer and autoimmune diseases.
Atara Biotherapeutics (NASDAQ: ATRA) has announced an agreement to sell its T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California, to FUJIFILM Diosynth Biotechnologies for USD 100 million. This strategic deal, which includes a long-term supply agreement, aims to reduce Atara's operating expenses and is expected to fund its operations into Q4 2023. Atara will retain its manufacturing expertise while FDB will expand the site to produce a wider range of allogeneic cell therapies. The deal is anticipated to close in April 2022, pending regulatory approval.
Atara Biotherapeutics (ATRA) announced significant findings linking Epstein-Barr virus (EBV) infection to multiple sclerosis (MS). A recent study published in Nature shows how EBV triggers immune cells to attack the myelin sheath in the central nervous system, potentially causing MS. The research indicates that nearly 100% of MS patients have been infected with EBV. Atara's investigational therapy, ATA188, targets EBV-infected B cells and is currently in a Phase 2 clinical study, highlighting its potential as a treatment option for MS.
Atara Biotherapeutics (NASDAQ: ATRA) announced significant milestones for its T-cell immunotherapies in 2021, including FDA Fast Track designation for ATA188 in multiple sclerosis, enhancing its market position. The company aims for tab-cel® to be the first allogeneic therapy approved in the EU for post-transplant lymphoproliferative disease, with decisions expected in 2022. Key presentations will occur at the J.P. Morgan Healthcare Conference on January 12. The company is also advancing CAR T programs targeting solid tumors. 2022 is projected to be a pivotal year for Atara's drug approvals.
Atara Biotherapeutics (NASDAQ: ATRA) announced the grant of 57,164 restricted stock units and options to purchase 64,925 shares of common stock to newly hired employees. These awards, approved by the Compensation Committee, are part of Atara’s 2018 Inducement Plan, intended as an incentive for new staff. The restricted stock units vest over four years, while stock options vest in a similar timeframe with a ten-year term. The exercise price for stock options is set at $16.89, equal to the stock's closing price on January 3, 2022.
Atara Biotherapeutics and Be The Match BioTherapies have extended their collaboration to supply healthy donor cells for Atara's off-the-shelf T-cell immunotherapy platform. This partnership aims to support patients with cancer and autoimmune diseases by utilizing Be The Match's extensive registry of over 22 million diverse HLA immune profiles. Atara's lead therapy, tab-cel, is currently under Phase 3 study and has recently submitted a marketing authorization application in the EU, marking a significant step towards availability for patients.